Cookies?
Library Header Image
LSE Research Online LSE Library Services

The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis

Romeo, Renee, Knapp, Martin ORCID: 0000-0003-1427-0215, Tyrer, P., Crawford, M. and Oliver-Africano, P. (2009) The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis. Journal of Intellectual Disability Research, 53 (7). pp. 633-643. ISSN 0964-2633

Full text not available from this repository.
Identification Number: 10.1111/j.1365-2788.2009.01180.x

Abstract

Background: Antipsychotic drugs are used in the routine treatment of adults with intellectual disabilities (ID) and challenging behaviour in the UK despite limited evidence of their effectiveness. There is no evidence on their cost-effectiveness. Methods: The relative cost-effectiveness of risperidone, haloperidol and placebo in treating individuals with an ID and challenging behaviour was compared from a societal perspective in a 26-week, double-blind, randomised controlled trial. Outcomes were changes in aggression and quality of life. Costs measured all service impacts and unpaid caregiver inputs. Results: After 26 weeks, patients randomised to placebo had lower costs compared with those in the risperidone and haloperidol treatment groups. Aggression was highest for patients treated with risperidone and lowest for patients treated with haloperidol; however, quality of life was lowest for patients treated with haloperidol and highest for patients treated with risperidone. Conclusion: The treatment of challenging behaviour in ID with antipsychotic drugs is not a cost-effective option.

Item Type: Article
Official URL: http://www3.interscience.wiley.com
Additional Information: © 2009 Blackwell Publishing Ltd.
Divisions: Social Policy
Care Policy and Evaluation Centre
Subjects: R Medicine > RA Public aspects of medicine
Date Deposited: 09 Oct 2009 09:56
Last Modified: 01 Nov 2024 04:19
URI: http://eprints.lse.ac.uk/id/eprint/25441

Actions (login required)

View Item View Item